COMPANY

Evommune

HQ: Palo Alto, CA source · evommune.com ↗ · West Coast

Location: Palo Alto, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Atopic Dermatitis Migraine Chronic Spontaneous Urticaria Chronic Inducible Urticaria Eczema Eczema Atopic Dermatitis Atopic Dermatitis Eczema EVO756 EVO301 EVO101

$125.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Jul 29, 2026 Trial start Phase 2: Study of EVO756 in Adults With Migraine source ↗
Feb 12, 2026 Raise Private placement: $125M (total, as published), announced Feb 12, 2026. Source: SEC filing. source ↗
Aug 26, 2025 Trial start 2: Phase 2b Study of EVO756 in Adults With Atopic Dermatitis source ↗
Mar 20, 2025 Trial start 2: Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) source ↗
Feb 13, 2025 Trial start Phase 2: Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis source ↗
Aug 14, 2024 Trial start Phase 2: A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria source ↗
Sep 27, 2022 Trial start Phase 2: Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis source ↗

Upcoming milestones

2027-10 (ESTIMATED) · Phase 2 · Study of EVO756 in Adults With Migraine · NCT07616128

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $125.0M. Last 2 years.

Feb 12, 2026 Private placement: $125M (total, as published), announced Feb 12, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07150845	Phase 2b Study of EVO756 in Adults With Atopic Dermatitis	2	Completed	Aug 26, 2025	Jul 23, 2026 (actual)
NCT07616128	Study of EVO756 in Adults With Migraine	Phase 2	Recruiting	Jul 29, 2026	2027-10 (estimated)
NCT06873516	Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)	2	Completed	Mar 20, 2025	May 29, 2026 (actual)
NCT06603220	A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria	Phase 2	Completed	Aug 14, 2024	May 8, 2025 (actual)
NCT06723405	Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis	Phase 2	Completed	Feb 13, 2025	Nov 17, 2025 (actual)
NCT05579899	Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis	Phase 2	Completed	Sep 27, 2022	Jul 27, 2023 (actual)